Changes to This Summary (09/25/2012)

The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.

Stage I, II, IIIA, and Operable IIIC Breast Cancer

Added text to state that at the time of the original report, overall survival (OS) was not statistically significantly improved; however, a 7-year update of results for disease-free survival (DFS) and OS demonstrated that four cycles of TC (docetaxel and cyclophosphamide) was superior to standard AC (doxorubicin plus cyclophosphamide) for both DFS and OS (cited Jones et al. as reference 196 and level of evidence 1iiA).

This summary is written and maintained by the PDQ Adult Treatment Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ NCI's Comprehensive Cancer Database pages.